Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors

1. Inzucchi SE , Bergenstal RM , Buse JB , Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79.

2. Handelsman Y , Mechanick JI , Blonde L , American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17: 1–53.

3. Rodbard HW , Jellinger PS , Davidson JA , Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540–59.

4. Neumiller JJ . Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011; 33: 528–76.

5. Holst JJ . The physiology of glucagon-like peptide-1. Physiol Rev 2007; 87: 1409–39.

6. Drucker KJ , Nauck MA . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–705.

7. Standards in medical care in diabetes–2012. Diabetes Care 2012; 35: S11–53.

8. Nathan DM , Buse JB , Davidson MB , Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.

9. Turner RC , Cull CA , Frighi V , Holman RR . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–12.

10. Eurich DT , Simpson SH , Majumdar SR , Johnson JA . Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes. Pharmacotherapy 2005; 25: 810–6.

11. Cook MN , Girman CJ , Stein PP , Alexander CM , Holman RR . Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005; 28: 995–1000.

12. McIntosh B , Cameron C , Singh SR , Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011; 5: E35–48.

13. Amiel SA , Dixon T , Mannt R , Jameson K . Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245–54.

14. Garber A , Henry R , Ratner R , Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–81.

15. Smith U . Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001; 121: 13–8.

16. Product information. Actos (pioglitazone). Deerfield, IL: Takeda Pharmaceuticals America, Inc., August 2012.

17. Charbonnel BH , Matthews DR , Schernthaner G , Hanefeld M , Brunetti P . A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399–405.

18. Aronoff S , Rosenblatt S , Braithwaite S , Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605–11.

19. Rosenstock J , Dailey G , Massi-Benedetti M , Fritsche A , Zhengning L , Salzman A . Reduced hypoglycemia risk with insulin glargine. Diabetes Care 2005; 28: 950–5.

20. Blonde L , Merilainen M , Karwe V , Raskin P . Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab 2009; 11: 623–31.

21. Rosenstock J , Davies M , Home PD , Larsen J , Koenen C , Schernthaner G . A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408–16.

22. Hollander P , Cooper J , Bregnhøj J , Pedersen CB . A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976–87.

23. Moretto TJ , Milton DR , Ridge TD , Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448–60.

24. Russell-Jones D , Cuddihy RM , Hanefeld M , Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 2012; 35: 252–8.

25. Aschner P , Kipnes MS , Lunceford JK , Sanchez M , Mickel C , Williams-Herman DE . Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632–7.

26. Raz I , Hanefeld M , Xu L , Caria C , Williams-Herman D , Khatami H . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564–71.

27. Rosenstock J , Sankoh S , List JF . Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 376–86.

28. Del Prato S , Barnett AH , Huisman H , Neubacher D , Woerle HJ , Dugi KA . Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type-2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258–67.

29. Klein S , Sheard NF , Pi-Sunyer X , et al.; American Diabetes Association; North American Association for the Study of Obesity; American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067–73.

30. Pi-Sunyer X , Blackburn G , Brancati FL , Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374–83.

31. DeFronzo RA , Okerson T , Viswanathan P , Guan X , Holcombe JH , MacConell L . Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943–52.

32. Holst JJ , Deacon CF . Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612–5.

33. Herman GA , Bergman A , Stevens C , Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612–9.

34. Drucker DJ , Buse JB , Taylor K , Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240–50.

35. Buse JB , Drucker DJ , Taylor KL , DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255–61.

36. Blevins T , Pullman J , Malloy J , DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301–10.

37. Buse JB , Rosenstock J , Sesti G , Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.

38. Blonde L , Klein EJ , Han J , Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436–47.

39. Wysham C , Bergenstal R , Malloy J , DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28: 705–14.

40. Klonoff DC , Buse JB , Nielsen LL , Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275–86.

41. Ratner RE , Maggs D , Nielsen LL , Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419–28.

42. Buse JB , Sesti G , Schmidt WE , Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300–3.

43. Buse JB , Ginsberg HN , Bakris GL , Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007; 30: 162–72.

44. Stettler C , Allemann S , Jüni P , Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27–38.

45. Holman RR , Paul SK , Bethel MA , Matthews DR , Neil AW . 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.

46. Gerstein HC , Miller ME , Genuth S , Long-term effects of intensive glucose-lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–28.

47. Tzoulaki I , Molokhia M , Curcin V , Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.

48. Evans JM , Ogston SA , Emslie-Smith A , Morris AD . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930–6.

49. Abdelmoneim AS , Hasenbank SE , Seubert JM , Brocks DR , Light PE , Simpson SH . Variations in tissue cell activity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012; 14: 130–8.

50. Nissen SE , Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71.

51. Dormandy JA , Charbonnel B , Eckland DJ , Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89.

52. Davidson MH . Cardiovascular effects of glucagon-like peptide-1 agonists. Am J Cardiol 2011; 108: 33B–41B.

53. Nikolaidis LA , Mankad S , Sokos GG , Effect of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–5.

54. Sokos GG , Nikolaidis LA , Mankad S , Elahi D , Shannon RP . Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Fail 2006; 12: 694–9.

55. Russell-Jones D , Vaag A , Schmitz O , Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–55.

56. Zinman B , Gerich J , Buse J , Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MET+TZD). Diabetes Care 2009; 32: 1224–30.

57. Marre M , Shaw J , Brändle M , Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–78.

58. Nauck M , Frid A , Hermansen K , Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 84–90.

59. Gutzwiller JP , Tschopp S , Bock A , Glucagon-like peptide 1 induces natriuresis in healthy participants and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055–61.

60. Lewington S , Clarke R , Qizilbash N , Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.

61. Bergenstal RM , Wysham C , MacConell L , Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–9.

62. Vilsbøll T , Zdravkovic M , Le-Thi T , Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608–10.

63. Charbonnel B , Karasik A , Liu J , Wu M , Meninger G . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638–43.

64. Rigby SP , Handelsman Y , Lai Y , Abby SL , Tao B , Jones MR . Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010; 16: 53–63.

65. Scott R , Loeys T , Davies MJ , Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959–69.

66. Wainstein J , Katz L , Engel SS , Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 409–18.

67. Williams-Herman D , Johnson J , Teng R , Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442–51.

68. Nauck MA , Meininger G , Sheng D , Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194–205.

69. Jadzinsky M , Pfützner A , Paz-Pacheco E , Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611–22.

70. Rosenstock J , Aguilar-Salinas C , Klein E , Effects of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401–11.

71. Brixner DI , McAdam-Marx C , Ye X , Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11: 1122–30.

72. Violante R , Oliveira HA , Yoon KH , A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 2012; 29: e417–24. DOI: 10.1111/j.1464-5491.2012.03624.x

73. Monami M , Cremasco F , Lamanna C , Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011: 215764.

74. Williams-Herman D , Engel SS , Round E , Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 2010; 10: 7.

75. Frederich R , Alexander JH , Fiedorek FT , A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16–27.

76. Johansen OE , Neubacher D , von Eynatten M , Patel S , Woerle H . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.

77. Fonseca VA . Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol 2011; 108: 52B–8B.

78. Weyer C , Bogardus C , Mott DM , Pratley RE . The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787–94.

79. Johnson JD , Luciani DS . Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2010; 654: 447–62.

80. Turner RC , Cull CA , Stratton IM , UK prospective diabetes study 16—overview of 6 years therapy of type II diabetes—a progressive disease. Diabetes 1995; 44: 1249–58.

81. Matveyenko AV , Butler PC . Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 2008; 10: 23–31.

82. Shah P , Vella A , Basu A , Basu R , Schwenk WF , Rizza RA . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053–9.

83. Efanova IB , Zaitsev SV , Zhivotovsky B , Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca²⁺ concentration. J Biol Chem 1998; 273: 33501–7.

84. Maedler K , Carr RD , Bosco D , Zuellig RA , Berney T , Donath MY . Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501–6.

85. Kahn SE , Haffner SM , Heise MA , Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–43.

86. Hull RL , Shen ZP , Watts MR , Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005; 54: 2235–44.

87. Lin CY , Gurlo T , Haataja L , Hsueh WA , Butler PC . Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90: 6678–86.

88. Mu J , Woods J , Zhou YP , Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695–704.

89. Reimer MK , Holst JJ , Ahren B . Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717–27.

90. Rolin B , Larsen MO , Gotfredsen CF , The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745–52.

91. Sturis J , Gotfredsen CF , Rømer J , GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123–32.

92. Chen J , Couto FM , Minn AH , Shalev A . Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006; 346: 1067–74.

93. Hanefeld M , Herman GA , Wu M , Mickel C , Sanchez M , Stein PP . Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007; 23: 1329–39.

94. Rosenstock J , Brazg R , Andryuk PJ , Lu K , Stein P . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556–68.

95. Nonaka K , Kakikawa T , Sato A , Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 291–8.

96. Hermansen K , Kipnes M , Luo E , Fanurik D , Khatami H , Stein P . Efficacy and safety of dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733–45.

97. Hollander P , Li J , Allen E , Saxagliptin added to thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810–9.

98. DeFronzo RA , Hissa MN , Garber AJ , The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009; 32: 1649–55.

99. Goldstein BJ , Feinglos MN , Lunceford JK , Johnson J , Williams-Herman DE . Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979–87.

100. Retnakaran R , Qi Y , Opsteen C , Vivero E , Zinman B . Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010; 12: 909–15.

101. Seck T , Nauck M , Sheng D , Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562–76.

102. Yoon KH , Shockey GR , Teng R , Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract 2011; 65: 154–64.

103. Chang AM , Jakobsen G , Sturis J , The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786–91.

104. Degn KB , Juhl CB , Sturis J , One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187–94.

105. Madsbad S , Schmitz O , Ranstam J , Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335–42.

106. Mari A , Degn K , Brock B , Rungby J , Ferrannini E , Schmitz O . Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007; 30: 2032–3.

107. Egan JM , Clocquet AR , Elahi D . The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282–90.

108. Buse JB , Henry RR , Han J , Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–35.

109. DeFronzo RA , Ratner RE , Han J , Kim DD , Fineman MS , Baron AD . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–100.

110. Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., December 2011.

111. Product information. Bydureon (exenatide extended-release). San Diego, CA: Amylin Pharmaceuticals, Inc., January 2012.

112. Product information. Januvia (sitagliptin). Whitehouse Station, NJ: Merck & Co., Inc., April 2012.

113. Product information. Onglyza (saxagliptin). Princeton, NJ: Bristol-Myers Squibb Company, December 2011.

114. Product information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk, April 2012.

115. Product information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals, Inc., September 2012.

116. Crespel A , De Boisvilliers F , Gros L , Kervran A . Effects of glucagon and glucagon-like peptide-1-(7–36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137: 3674–80.

117. Lamari Y , Boissard C , Moukhtar MS , Jullienne A , Rosselin G , Garel JM . Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 1996; 393: 248–52.

118. Madsen LW , Knauf JA , Gotfredsen C , GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153: 1538–47.

119. Knudsen LB , Madsen LW , Andersen S , Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473–86.

120. Gier B , Butler PC , Lai CK , Kirakossian D , DeNicola MM , Yeh MW . Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012; 97: 121–31.

121. Food and Drug Administration. Victoza. Approval. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200Orig1s000lbledt.pdf. (accessed 2013 Mar 22).

122. Food and Drug Administration. Bydureon. Approval. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumR.pdf (accessed 2013 Mar 22).

123. Noel RA , Braun DK , Patterson RE , Bloomgren GL . Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2004; 27: 2628–35. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712. (accessed 2013 Mar 22).

124. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta). October 2007 update. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712.htm (accessed 2012 Jun 18). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713. (accessed 2013 Mar 22).

125. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta). August 2008 update. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucml124713.htm (accessed 2012 Jun 18).

126. Food and Drug Administration. Byetta (exenatide). Injections detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). November 2009, November 2010, and October 2011. http://www.Fda.gov/Safety/MedWatch/SafetyInformation/ucm194556.htm (accessed 2012 Jun 18).

127. Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet)—acute pancreatitis. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm (accessed 2012 Jun 18).

128. Garg R , Chen W , Pendergrass M . Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349–54.

129. Wenten M , Gaebler JA , Hussein M , Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012:29: 1412–8. DOI: 10.1111/j.1464-5491.2012.03652.x

130. MacConell L , Brown C , Gurney K , Han J . Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012; 5: 29–41.

131. Food and Drug Administration. Victoza (liraglutide [rDNA origin]) injection: REMS—risk of thyroid C-cell tumors, acute pancreatitis (posted 06/13/2011). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm (accessed 2012 Jun 18).

132. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013 Feb 25:E1–6 [Epub ahead of print].

133. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. www.fda.gov/Drugs/DrugSafety/ucm343187.htm (accessed 2013 Mar 27).

134. Pioglitazone. Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=PIOGLITAZONE&searchType=redbookProductName&searchTermId=40205&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Epioglitazone. (accessed 2012 Nov 5).

135. Lantus. Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/N_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=LANTUS%20SOLOSTAR&searchType=redbookProductName&searchTermId=19914&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5ELantus. (accessed 2012 Nov 5).

136. Levemir. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=LEVEMIR&searchType=redbookProductName&searchTermId=18914&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Elevemir. (accessed 2012 Nov 5).

137. Byetta. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=BYETTA&searchType=redbookProductName&searchTermId=17855&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Ebyetta. (accessed 2012 Nov 5).

138. Bydureon. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=BYDUREON&searchType=redbookProductName&searchTermId=39363&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Ebydureon. (accessed 2012 Nov 5).

139. Victoza. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=VICTOZA&searchType=redbookProductName&searchTermId=22668&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Evictoza. (accessed 2012 Nov 5).

140. Januvia. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=JANUVIA&searchType=redbookProductName&searchTermId=19065&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Ejanuvia. (accessed 2012 Nov 5).

141. Onglyza. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=ONGLYZA&searchType=redbookProductName&searchTermId=36695&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Eonglyza. (accessed 2012 Nov 5).

142. Tradjenta. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=TRADJENTA&searchType=redbookProductName&searchTermId=38414&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Etradjenta. (accessed 2012 Nov 5).